Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul M Copeland

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The Journal of Clinical Psychiatry|February 12, 2005
Medical morbidity and mortality in schizophrenia: guidelines for psychiatristsDonald C Goff, Corinne Cather, A Eden Evins, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|March 4, 2010
Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidoneDavid C Henderson, Bikash Sharma, Xiaoduo Fan, et al.
Schizophrenia Research|May 14, 2011
Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophreniaDavid C Henderson, Oliver Freudenreich, Christina P C Borba, et al.
AJR. American Journal of Roentgenology|June 24, 2006
Adrenocortical carcinoma: contrast washout characteristics on CTJames M A Slattery, Michael A Blake, Mannudeep K Kalra, et al.
Journal of Psychiatric Practice|July 24, 2009
Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapineDavid C Henderson, Xiaoduo Fan, Bikash Sharma, et al.
Journal of Clinical Psychopharmacology|June 11, 2009
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patientsDavid C Henderson, Xiaoduo Fan, Paul M Copeland, et al.
Obesity (Silver Spring, Md.)|September 1, 2022
Results of a 2-year lifestyle intervention for type 2 diabetes: the Reach Ahead for Lifestyle and Health-Diabetes randomized controlled trialDeborah J Wexler, Yuchiao Chang, Douglas E Levy, et al.
The Journal of Clinical Psychiatry|September 29, 2005
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic studyDavid C Henderson, Dana D Nguyen, Paul M Copeland, et al.
Schizophrenia Research|September 29, 2014
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolismBrenda Vincenzi, Shannon Stock, Christina P C Borba, et al.
The American Journal of Psychiatry|May 3, 2005
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gainDavid C Henderson, Paul M Copeland, Tara B Daley, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Journal of Clinical Psychiatry|February 12, 2005
Medical morbidity and mortality in schizophrenia: guidelines for psychiatristsDonald C Goff, Corinne Cather, A Eden Evins, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|March 4, 2010
Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidoneDavid C Henderson, Bikash Sharma, Xiaoduo Fan, et al.
Schizophrenia Research|May 14, 2011
Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophreniaDavid C Henderson, Oliver Freudenreich, Christina P C Borba, et al.
AJR. American Journal of Roentgenology|June 24, 2006
Adrenocortical carcinoma: contrast washout characteristics on CTJames M A Slattery, Michael A Blake, Mannudeep K Kalra, et al.
Journal of Psychiatric Practice|July 24, 2009
Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapineDavid C Henderson, Xiaoduo Fan, Bikash Sharma, et al.
Journal of Clinical Psychopharmacology|June 11, 2009
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patientsDavid C Henderson, Xiaoduo Fan, Paul M Copeland, et al.
Obesity (Silver Spring, Md.)|September 1, 2022
Results of a 2-year lifestyle intervention for type 2 diabetes: the Reach Ahead for Lifestyle and Health-Diabetes randomized controlled trialDeborah J Wexler, Yuchiao Chang, Douglas E Levy, et al.
The Journal of Clinical Psychiatry|September 29, 2005
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic studyDavid C Henderson, Dana D Nguyen, Paul M Copeland, et al.
Schizophrenia Research|September 29, 2014
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolismBrenda Vincenzi, Shannon Stock, Christina P C Borba, et al.
The American Journal of Psychiatry|May 3, 2005
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gainDavid C Henderson, Paul M Copeland, Tara B Daley, et al.
Pageof 3